



*Supplemental Figures*

# Ocoxin Increases the Antitumor Effect of BRAF Inhibition and Reduces Cancer Associated Fibroblast-Mediated Chemo-resistance and Protumoral Activity in Metastatic Melanoma


Aitor Benedicto <sup>1</sup>, Iera Hernández-Unzueta <sup>1</sup>, Eduardo Sanz <sup>2</sup> and Joana Márquez <sup>1\*</sup>




**Figure S1.** In vivo treatment administration groups.




**Figure S2.** The expression of MITF in YUMM 1.7 melanoma cell line by Flow Cytometry.




**Figure S3.** Apoptotic effect of the combination of Ocoxin and Vemurafenib in melanoma cells.




**Figure S4.** Apoptotic effect of the combination of Ocoxin and Vemurafenib in COLO-800 melanoma cells.




**Figure S5.** Apoptotic effect of the combination of Ocoxin and Vemurafenib in HT-144 melanoma cells.




**Figure S6.** Cytokine Antibody array membranes of control and Ocoxin treated cell secretomes.




**Figure S7.** Percentage of mice with YUMM 1.7 cell lung metastasis.



**Figure S8.** 3T3 fibroblast viability upon Ocoxin treatment.



**Figure S9.** The western blot obtained for p53 (24 h).



**Figure S10.** Cell cycle for 24 hours.